Physician profile
Tania Levi
NPI 1629058813
$9,180.09
in general payments reported to CMS, 2019-2025
58 companies · $625 in 2025
The $625 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $1,482 · 2021: $1,734 · 2022: $1,312 · 2023: $1,140 · 2024: $1,019 · 2025: $625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,783.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,126.74 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $1,033.13 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $769.44 | 2019-2025 | |
| Novo Nordisk INC | $574.75 | 2019-2025 | Wegovy, Rybelsus, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $564.01 | 2019-2025 | Jardiance |
| Pfizer INC. | $511.91 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $388.83 | 2019-2024 | Trintellix |
| Glaxosmithkline, LLC. | $344.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Allergan, INC. | $324.57 | 2019-2020 | |
| Amarin Pharma, INC. | $238.17 | 2019-2022 | |
| Lundbeck LLC | $203.20 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $192.08 | 2019-2024 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $172.05 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Teva Pharmaceuticals USA, INC. | $170.57 | 2019-2020 | |
| Bausch Health US, LLC | $155.80 | 2019-2024 | Aplenzin, Wellbutrin |
Show all 57 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Levi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.